Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01869803 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Gemtuzumab ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (NCT01869803)

Trial Description
This clinical trial studies the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in treating patients with relapsed or refractory acute myeloid leukemia or acute promyelocytic leukemia (APL). Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. This trial is sponsored by the Comprehensive Cancer Center of Wake Forest University. [1]

Study Data

  • Condition:
    • Adult Myeloid Leukemia (AML)
    • Adult Acute Promyelocytic Leukemia (M3)
    • Childhood Acute Promyelocytic Leukemia (M3)
    • Recurrent Adult Acute Myeloid Leukemia
    • Recurrent Childhood Acute Myeloid Leukemia
  • Interventions:
    • Drugs used in this trial
      • gemtuzumab ozogamicin (Mylotarg®; Pfizer (Wyeth))
      • Other: laboratory biomarker analysis
  • Phase: 0
  • Estimated Enrollment: 30
  • Start: August 2013
  • Estimated Primary Completion: August 2020
  • Last verified: July 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar